Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in VRTX — Vertex Pharmaceuticals Inc / Ma

CIK 1423053 MIAMI, FL
Back to VRTX Full portfolio

Position in VRTX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$253,545,893
+$102,035,765 QoQ
Shares Held
510,430
+50.4% QoQ
Ownership
0.201%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#62
of 1,735 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in VRTX Over Time

Shares Held

Position Value (USD)

Derivatives in VRTX

reported options exposure · as of Jun 30, 2026
CallValue
$121,500,158
CallShares
244,600
PutValue
$66,859,858
PutShares
134,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,855,369 across 436 Biotechnology names. VRTX ranks #5 (4.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ONC
BeOne Medicines Ltd.
 1,425,517 $406,229,578
2 BBIO
BridgeBio Pharma, Inc.
 3,760,028 $280,046,885
3 INSM
INSMED Inc
 2,556,973 $272,624,460
4 MDGL
Madrigal Pharmaceuticals, Inc.
 507,233 $272,358,759
5 VRTX
Vertex Pharmaceuticals Inc / Ma
This page 		510,430 $253,545,893
6 JAZZ
Jazz Pharmaceuticals plc
 1,006,676 $242,578,715
7 MANE
Veradermics, Inc
 1,877,775 $230,853,658
8 ROIV
Roivant Sciences Ltd.
 5,576,261 $197,343,876

All Filings in VRTX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $121,500,158 244,600
2026-06-30 $66,859,858 134,600
2026-06-30 $253,545,893 510,430
2026-03-31 $151,510,128 339,298
2026-03-31 $100,069,614 224,100
2026-03-31 $30,409,374 68,100
2025-12-31 $51,909,720 114,500
2025-12-31 $112,614,624 248,400
2025-12-31 $193,611,921 427,060
2025-09-30 $67,950,322 173,502
2025-09-30 $107,857,656 275,400
2025-09-30 $53,263,040 136,000
2025-06-30 $55,694,520 125,100
2025-06-30 $141,929,760 318,800
2025-06-30 $12,833,780 28,827
2025-03-31 $2,433,311 5,019
2025-03-31 $134,295,140 277,000
2025-03-31 $50,615,208 104,400
2024-12-31 $65,310,288 162,181
2024-12-31 $69,183,860 171,800
2024-12-31 $139,777,170 347,100
2024-09-30 $43,810,536 94,200
2024-09-30 $23,361,898 50,232
2024-09-30 $97,434,260 209,500
2024-06-30 $52,590,384 112,200
2024-06-30 $49,025,767 104,595
2024-06-30 $63,464,688 135,400
2024-03-31 $62,283,490 149,000
2024-03-31 $34,265,533 81,973
2024-03-31 $61,113,062 146,200
2023-12-31 $55,296,351 135,900
2023-12-31 $76,291,875 187,500
2023-12-31 $132,922,824 326,680
2023-09-30 $48,961,792 140,800
2023-09-30 $47,709,928 137,200
2023-09-30 $9,647,698 27,744
2023-06-30 $34,627,944 98,400
2023-06-30 $39,202,774 111,400
2023-06-30 $39,765 113
2023-03-31 $48,615,301 154,300
2023-03-31 $39,352,243 124,900
2023-03-31 $26,404,756 83,806
2022-12-31 $54,666,054 189,300
2022-12-31 $58,798,784 203,611
2022-12-31 $57,496,098 199,100
2022-09-30 $65,088,592 224,800
2022-09-30 $92,392,214 319,100
2022-09-30 $3,985,517 13,765
2022-06-30 $118,661,769 421,100
2022-06-30 $81,662,742 289,800

Report a Problem

Category
Description
Email (optional, for follow-up)